Study Summary
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.
Want to learn more about this trial?
Request More InfoInterventions
JY231 InjectionDRUG
This study employs two pretreatment regimens:
In the lymphodepletion regimen, upon enrollment, subjects undergo leukapheresis followed by 3-5 days of lymphodepleting therapy with fludarabine and cyclophosphamide, culminating in intravenous infusion of JY231 and autologous patient PBMCs via a double-lumen catheter; in the non-lymphodepletion regimen, subjects receive direct intravenous injection of the JY231 preparation immediately after enrollment.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China | Wuhan | Hubei | China |